CommercialCoverageMedium impact
Focinvez (fosaprepitant)
Blue Cross & Blue Shield of Mississippi·MS · Oncology·Medical Policy
Effective date
Jun 15, 2026
We identified it
Jun 20, 2026
Summary
BCBS Mississippi has added a new policy declaring Focinvez (fosaprepitant) injections as not medically necessary for chemotherapy-induced nausea and vomiting prevention, citing availability of formulary alternatives. Prior authorization is required for any services related to delivery or administration of this medication.
Action Required
By June 15, 2026: Billing team must update system to flag HCPCS code J1434 (fosaprepitant injection) as requiring prior authorization for BCBS Mississippi members. Notify oncology providers that Focinvez is considered not medically necessary and to use covered formulary alternatives. Claims for J1434 will be denied without prior authorization approval through BCBSMS PA review process.